title: Asthma-related medication use among children in the United States.
abstract: BACKGROUND
  Asthma is one of the most common chronic conditions in children and has a major impact on health care use and quality of life. The Best Pharmaceuticals for Children Act mandates the federal government to sponsor pediatric studies of drugs approved for use in the United States but lacking evaluation in the pediatric population and lacking interest of commercial sponsors. As input into the drug selection and prioritization process, information is needed on the percentage of children who receive asthma-related medications.
  
  
  OBJECTIVE
  To estimate the percentage of children who receive asthma-related medications.
  
  
  METHODS
  Retrospective analysis of outpatient medical and drug claims from members of commercial health care insurance plans enrolled any time from January 1, 2004, through December 31, 2005. The study population included 4,259,103 children throughout the United States aged birth through 17 years.
  
  
  RESULTS
  Fifteen percent of all children were dispensed an asthma-related medication. Among 218,943 children with an asthma diagnosis, 188,286 (86%) had a dispensed asthma-related medication at any time during the 2-year study period. Among children without any asthma diagnoses, 398,880 (10%) had a dispensed medication. Fifty-nine percent of children with an asthma diagnosis were dispensed an anti-inflammatory medication within 90 days after a claim with a diagnosis of asthma.
  
  
  CONCLUSIONS
  Asthma-related medications are dispensed to a large percentage of the pediatric population, including many who do not have claims with asthma diagnoses listed. Data on the pharmacokinetics and safety of these drugs in children are largely unknown and difficult to obtain. Clinical studies that use new tools and approaches are needed to resolve this information gap.
authors.affiliation: Westat, Rockville, Maryland 20850, USA. JamesKorelitz@Westat.com
authors.forename: James J
authors.initials: JJ
authors.lastname: Korelitz
authors.forename: Julie M
authors.initials: JM
authors.lastname: Zito
authors.forename: Norma I
authors.initials: NI
authors.lastname: Gavin
authors.forename: Mary N
authors.initials: MN
authors.lastname: Masters
authors.forename: Diane
authors.initials: D
authors.lastname: McNally
authors.forename: Debra E
authors.initials: DE
authors.lastname: Irwin
authors.forename: Kelly
authors.initials: K
authors.lastname: Kelleher
authors.forename: James
authors.initials: J
authors.lastname: Bethel
authors.forename: Yiling
authors.initials: Y
authors.lastname: Xu
authors.forename: Judith
authors.initials: J
authors.lastname: Rubin
authors.forename: Donald R
authors.initials: DR
authors.lastname: Mattison
mesh_terms: D000293:Adolescent; D018927:Anti-Asthmatic Agents / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy* / Q000453:epidemiology; D002648:Child; D002675:Child, Preschool; D004363:Drug Utilization / Q000706:statistics & numerical data*; D005260:Female; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D015995:Prevalence; D012189:Retrospective Studies; D014481:United States / Q000453:epidemiology
chemical_list: D018927:Anti-Asthmatic Agents